Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer

Conclusions
The presence of asymptomatic LVSD, abnormal cardiac biomarkers and cardiac risk factors in participants treated with trastuzumab and anthracycline at least 5 years previously is common, even in those with normal LVEF on completion of treatment. Our findings reinforce the relevance of comprehensive evaluation of cardiovascular risk factors following completion of cancer therapy, in addition to LVEF assessment.

Source: Heart - April 15, 2024 Category: Cardiology Authors: Glen, C., Morrow, A., Roditi, G., Hopkins, T., Macpherson, I., Stewart, P., Petrie, M. C., Berry, C., Epstein, F., Lang, N. N., Mangion, K. Tags: Open access Special populations Source Type: research